{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=8", "query": { "condition": "Cancer of the Stomach", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 951, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T10:33:23.843Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02970539", "title": "Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Esophageal Cancer", "Gastro-esophageal Cancer" ], "interventions": [ { "name": "Oraxol", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Athenex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-12-08", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2022-02-16", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02970539" }, { "nct_id": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IV Breast Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2012-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705340" }, { "nct_id": "NCT04504916", "title": "A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple-negative Breast Cancer", "Non-squamous Non-small-cell Lung Cancer", "NSCLC", "Estrogen-receptor-positive Breast Cancer", "Progesterone-receptor-positive Breast Cancer", "Estrogen-receptor-negative Breast Cancer", "ER-negative Breast Cancer", "Progesterone-receptor Negative Breast Cancer", "PR-negative Breast Cancer", "HER2-negative Breast Cancer", "ER-positive Breast Cancer", "PR-positive Breast Cancer", "Platinum-resistant Ovarian Cancer", "Gastric Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2020-10-07", "completion_date": "2023-06-12", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 8, "location_summary": "Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504916" }, { "nct_id": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Breast Cancer", "Gastric Cancer", "Non-small Cell Lung Cancer", "Cervical Cancer", "Endocervical Cancer", "Squamous Cell Carcinoma of Head and Neck", "Bladder Urothelial Cancer", "Colorectal Carcinoma", "Esophageal Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Prostate Cancer", "Melanoma", "Mesothelioma", "Cholangiocarcinoma" ], "interventions": [ { "name": "NGM831", "type": "DRUG" }, { "name": "NGM831 plus pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-03-31", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 9, "location_summary": "Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05215574" }, { "nct_id": "NCT03154190", "title": "Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia", "Brain Glioblastoma", "Estrogen Receptor Negative", "Extensive Stage Small Cell Lung Carcinoma", "Head and Neck Carcinoma", "HER2/Neu Negative", "Hormone-Resistant Prostate Cancer", "Limited Stage Small Cell Lung Carcinoma", "Myelodysplastic Syndrome", "Progesterone Receptor Negative", "Progressive Disease", "Recurrent Carcinoma", "Stage II Pancreatic Cancer", "Stage II Rectal Cancer", "Stage IIA Pancreatic Cancer", "Stage IIA Rectal Cancer", "Stage IIB Pancreatic Cancer", "Stage IIB Rectal Cancer", "Stage IIC Rectal Cancer", "Stage III Colon Cancer", "Stage III Esophageal Cancer", "Stage III Gastric Cancer", "Stage III Non-Small Cell Lung Cancer", "Stage III Ovarian Cancer", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Skin Melanoma", "Stage IIIA Colon Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Rectal Cancer", "Stage IIIA Skin Melanoma", "Stage IIIB Colon Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Rectal Cancer", "Stage IIIB Skin Melanoma", "Stage IIIC Colon Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Rectal Cancer", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Bone Sarcoma", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Ovarian Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IV Soft Tissue Sarcoma", "Stage IVA Bone Sarcoma", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Bone Sarcoma", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Supportive Care", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2017-08-08", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 1, "location_summary": "Fullerton, California", "locations": [ { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03154190" }, { "nct_id": "NCT00003137", "title": "Irinotecan in Treating Patients With Advanced Cancer of the Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "1997-12", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003137" }, { "nct_id": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastric Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2024-06-24", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 375, "location_summary": "Little Rock, Arkansas • Anaheim, California • Baldwin Park, California + 286 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06203600" }, { "nct_id": "NCT01938638", "title": "Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "BAY1143572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 80, "start_date": "2013-09-26", "completion_date": "2016-09-19", "has_results": false, "last_update_posted_date": "2017-10-20", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 6, "location_summary": "Fayetteville, Arkansas • Boston, Massachusetts • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01938638" }, { "nct_id": "NCT07221149", "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Folfox", "type": "DRUG" }, { "name": "Capox", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 690, "start_date": "2026-03-13", "completion_date": "2032-09-11", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221149" }, { "nct_id": "NCT04483349", "title": "Assessment of What Patients and Healthcare Providers Value", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 397, "start_date": "2020-06-11", "completion_date": "2022-08-11", "has_results": false, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-10-21T10:33:23.843Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04483349" } ] }